BACKGROUND: Non-palliative resection of the primary tumor in stage IV breast cancer is controversial. Our aim was to determine whether surgery improves survival in stage IV patients. METHODS: We reviewed records of all stage IV breast cancer patients (1990-2000) at our institution. Data collection included demographics, metastasis sites, treatment, and survival. Survival was compared between metastasis type, hormonal therapy versus no hormonal therapy, chemotherapy versus no chemotherapy, radiation versus no radiation, and surgery versus no surgery. To ascertain local therapy effects while accounting for chemotherapy, we analyzed survival among chemotherapy alone versus chemotherapy with radiation versus chemotherapy with surgery. We also performed multivariate analysis by multiple linear regression. RESULTS: Of 157 patients, 58 (37%) had bone-only metastases, 99 (63%) had visceral metastases. Both groups had a 17-mo median survival. Eighty (51%) received hormonal therapy while 77 (49%) did not. Both groups had a 15-mo median survival. Eighty-four (54%) received chemotherapy with a 25-mo median survival versus 8 mo for 73 (46%) not receiving chemotherapy, Wilcoxon (P < 0.0001), and log-rank (P = 0.02). Fifty-eight (37%) received radiation and 99 (63%) did not, with both groups having a 17-mo median survival. Fifty-two (33%) with surgery to the breast primary had a 25-mo median survival, while 105 (67%) without surgery had a 13-mo median survival, Wilcoxon (P = 0.004) and log-rank (P = 0.06). Among patients receiving chemotherapy, 37 with chemotherapy alone had a 21-mo median survival versus 40 mo for the 14 with chemotherapy and radiation and 22 mo for the 33 with chemotherapy and surgery. These differences were not significant by Wilcoxon (P = 0.41) or log-rank (P = 0.36). Multivariate analysis determined chemotherapy as the only factor associated with improved survival (P = 0.02). CONCLUSION: Our data, when standardized for chemotherapy, suggests loco-regional therapy does not improve survival. Copyright (c) 2010 Elsevier Inc. All rights reserved.
BACKGROUND: Non-palliative resection of the primary tumor in stage IV breast cancer is controversial. Our aim was to determine whether surgery improves survival in stage IV patients. METHODS: We reviewed records of all stage IV breast cancerpatients (1990-2000) at our institution. Data collection included demographics, metastasis sites, treatment, and survival. Survival was compared between metastasis type, hormonal therapy versus no hormonal therapy, chemotherapy versus no chemotherapy, radiation versus no radiation, and surgery versus no surgery. To ascertain local therapy effects while accounting for chemotherapy, we analyzed survival among chemotherapy alone versus chemotherapy with radiation versus chemotherapy with surgery. We also performed multivariate analysis by multiple linear regression. RESULTS: Of 157 patients, 58 (37%) had bone-only metastases, 99 (63%) had visceral metastases. Both groups had a 17-mo median survival. Eighty (51%) received hormonal therapy while 77 (49%) did not. Both groups had a 15-mo median survival. Eighty-four (54%) received chemotherapy with a 25-mo median survival versus 8 mo for 73 (46%) not receiving chemotherapy, Wilcoxon (P < 0.0001), and log-rank (P = 0.02). Fifty-eight (37%) received radiation and 99 (63%) did not, with both groups having a 17-mo median survival. Fifty-two (33%) with surgery to the breast primary had a 25-mo median survival, while 105 (67%) without surgery had a 13-mo median survival, Wilcoxon (P = 0.004) and log-rank (P = 0.06). Among patients receiving chemotherapy, 37 with chemotherapy alone had a 21-mo median survival versus 40 mo for the 14 with chemotherapy and radiation and 22 mo for the 33 with chemotherapy and surgery. These differences were not significant by Wilcoxon (P = 0.41) or log-rank (P = 0.36). Multivariate analysis determined chemotherapy as the only factor associated with improved survival (P = 0.02). CONCLUSION: Our data, when standardized for chemotherapy, suggests loco-regional therapy does not improve survival. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: S Samiee; P Berardi; N Bouganim; L Vandermeer; A Arnaout; S Dent; D Mirsky; M Chasen; J M Caudrelier; M Clemons Journal: Curr Oncol Date: 2012-08 Impact factor: 3.677
Authors: Omar M Rashid; Masayuki Nagahashi; Subramaniam Ramachandran; Laura Graham; Akimitsu Yamada; Sarah Spiegel; Harry D Bear; Kazuaki Takabe Journal: Surgery Date: 2013-03-13 Impact factor: 3.982
Authors: Julie E Lang; Welela Tereffe; Melissa P Mitchell; Roshni Rao; Lei Feng; Funda Meric-Bernstam; Isabelle Bedrosian; Henry M Kuerer; Kelly K Hunt; Gabriel N Hortobagyi; Gildy V Babiera Journal: Ann Surg Oncol Date: 2013-01-11 Impact factor: 5.344
Authors: Jetske Ruiterkamp; Adri C Voogd; Vivianne C G Tjan-Heijnen; Koop Bosscha; Yvette M van der Linden; Emiel J Th Rutgers; Epie Boven; Maurice J C van der Sangen; Miranda F Ernst Journal: BMC Surg Date: 2012-04-02 Impact factor: 2.102